Curis Inc. Upcoming Presentation at Healthcare Conference
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on pioneering the development of emavusertib (CA-4948), an innovative orally administered small molecule IRAK4 inhibitor, has recently made an announcement regarding its participation in a notable healthcare and technology conference.
Fireside Chat Participation by CEO
At the Jones Healthcare and Technology Innovation Conference, James Dentzer, the President and CEO of Curis, will engage in a captivating fireside chat as well as deliver a company presentation. The conference is set to highlight the significant advancements and future potential of emavusertib in oncology.
All Bets on IRAK4 Fireside Chat
During this fireside chat, attendees will have the opportunity to gain insights into the transformative potential of IRAK4 inhibitors in targeted cancer therapies. The chat is scheduled to commence at 4:30 PM ET (1:30 PM PT), providing a platform for in-depth discussions regarding Curis's strategic direction and the future of emavusertib.
Curis's Company Presentation Details
Following the fireside chat, Curis will hold a company presentation at 5:00 PM ET (2:00 PM PT). This presentation will cover the company’s recent developments, focusing on clinical pipeline updates and their strategic initiatives within the biopharmaceutical landscape. Attendees are encouraged to participate in this session to learn more about Curis's groundbreaking work.
Joining the Conference Online
For those unable to attend in person, an opportunity to view the fireside chat and company presentation will be available through a live webcast. Participants can conveniently access this via the Curis investor relations webpage.
The Significance of Emavusertib
Curis is directing its efforts toward advancing emavusertib through various clinical trials, showcasing its potential against conditions like lymphoma and leukemia. The drug is currently under evaluation in the Phase 1/2 TakeAim Lymphoma study, which aims to assist patients dealing with relapsed or refractory primary central nervous system lymphoma. Furthermore, emavusertib is being analyzed as part of monotherapy and combination therapy studies, highlighting its versatility in treating acute myeloid leukemia and high-risk myelodysplastic syndrome.
About Curis, Inc.
Curis is committed to not only pioneering the development of innovative therapies like emavusertib, but also prioritizing patient needs by focusing on hard-to-treat cancers. This dedication has earned the drug Orphan Drug Designation from the U.S. FDA for multiple indications, marking a critical recognition of its therapeutic potential. With an exclusive license to emavusertib in collaboration with Aurigene, Curis is poised to make significant contributions to oncology.
Frequently Asked Questions
What is emavusertib?
Emavusertib is an orally available, small molecule IRAK4 inhibitor that is under development for treating various forms of cancer, including lymphoma and leukemia.
When will the fireside chat take place?
The fireside chat is scheduled for 4:30 PM ET on the day of the conference.
How can I access the presentations?
The live webcast and archived presentations will be available on the Curis investor relations website.
What are some of the clinical trials involving emavusertib?
Emavusertib is currently involved in trials like the Phase 1/2 TakeAim studies for lymphoma and leukemia.
What is the focus of Curis, Inc.?
Curis focuses on developing innovative treatments for cancers, particularly through targeted therapies with the potential to improve patient outcomes.
